Cargando…
Combining SJ733, an oral ATP4 inhibitor of Plasmodium falciparum, with the pharmacokinetic enhancer cobicistat: An innovative approach in antimalarial drug development
BACKGROUND: SJ733, a newly developed inhibitor of P. falciparum ATP4, has a favorable safety profile and rapid antiparasitic effect but insufficient duration to deliver a single-dose cure of malaria. We investigated the safety, tolerability, and pharmacokinetics of a multidose SJ733 regimen and a si...
Autores principales: | Gaur, Aditya H., Panetta, John C., Smith, Amber M., Dallas, Ronald H., Freeman, Burgess B., Stewart, Tracy B., Tang, Li, John, Elizabeth, Branum, Kristen C., Patel, Nehali D., Ost, Shelley, Heine, Ryan N., Richardson, Julie L., Hammill, Jared T., Bebrevska, Lidiya, Gusovsky, Fabian, Maki, Noritsugu, Yanagi, Toshiharu, Flynn, Patricia M., McCarthy, James S., Chalon, Stephan, Guy, R. Kiplin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127571/ https://www.ncbi.nlm.nih.gov/pubmed/35598441 http://dx.doi.org/10.1016/j.ebiom.2022.104065 |
Ejemplares similares
-
Similarly efficacious anti-malarial drugs SJ733 and pyronaridine differ in their ability to remove circulating parasites in mice
por: SheelaNair, Arya, et al.
Publicado: (2022) -
Plasmid-free CRISPR/Cas9 genome editing in Plasmodium falciparum confirms mutations conferring resistance to the dihydroisoquinolone clinical candidate SJ733
por: Crawford, Emily D., et al.
Publicado: (2017) -
Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study
por: McCarthy, James S, et al.
Publicado: (2017) -
Complete Draft Genome Sequence of Escherichia coli JF733
por: Kleiner, Gabriele R. M., et al.
Publicado: (2016) -
On the Mechanism of Action of SJ-172550 in Inhibiting the Interaction of MDM4 and p53
por: Bista, Michal, et al.
Publicado: (2012)